Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824818 · ClinicalTrials.gov registry record · NA
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
A NA study of Prostate Cancer and Elderly, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 155
- Enrollment target
- 2
- Study locations
NCT06824818: Recruiting NA study of Prostate Cancer and Elderly, sponsored by University of Chicago.
NCT06824818 is a NA study of Prostate Cancer and Elderly that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 155 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06824818, a NA study of Prostate Cancer and Elderly, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Primary Outcome
Fraction of patients maintaining castrate testosterone levels
Conditions Studied
Interventions
- BEHAVIORAL LHRH Agonist Therapy Discontinuation
Study Locations (2)
Illinois
- The University of Illinois at Chicago (UIC) - Chicago
- UChicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT06824818 shows while recruiting
NCT06824818 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which LHRH Agonist Therapy Discontinuation is the first listed.
NCT06824818 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06824818 about?
NCT06824818 is a clinical study titled "Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients". This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not req...
What is the current status of trial NCT06824818?
This trial is currently recruiting. It is a NA study. The enrollment target is 155 participants. The study started on 2026-06. Estimated completion is 2027-06.
What conditions does trial NCT06824818 study?
This clinical trial studies the following conditions: Prostate Cancer, Elderly.
What interventions are being tested in trial NCT06824818?
The interventions under investigation include: LHRH Agonist Therapy Discontinuation (BEHAVIORAL).
Who is sponsoring clinical trial NCT06824818?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824818 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06824818's enrollment target sits among peer trials
155 258th of 735 higher than 478 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia